- Home
- TCRX vs NUKK Comparison
TCRX vs NUKK Comparison
Compare TCRX & NUKK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TCRX
- NUKK
- Stock Information
- Founded
- TCRX 2018
- NUKK 2013
- Country
- TCRX United States
- NUKK United States
- Employees
- TCRX N/A
- NUKK N/A
- Industry
- TCRX Biotechnology: Pharmaceutical Preparations
- NUKK Blank Checks
- Sector
- TCRX Health Care
- NUKK Finance
- Exchange
- TCRX Nasdaq
- NUKK Nasdaq
- Market Cap
- TCRX 90.5M
- NUKK 77.4M
- IPO Year
- TCRX 2021
- NUKK N/A
- Fundamental
- Price
- TCRX $1.45
- NUKK $13.56
- Analyst Decision
- TCRX Strong Buy
- NUKK
- Analyst Count
- TCRX 6
- NUKK 0
- Target Price
- TCRX $9.50
- NUKK N/A
- AVG Volume (30 Days)
- TCRX 774.8K
- NUKK 235.9K
- Earning Date
- TCRX 05-06-2025
- NUKK 06-10-2025
- Dividend Yield
- TCRX N/A
- NUKK N/A
- EPS Growth
- TCRX N/A
- NUKK N/A
- EPS
- TCRX N/A
- NUKK N/A
- Revenue
- TCRX $4,421,000.00
- NUKK N/A
- Revenue This Year
- TCRX $68.86
- NUKK N/A
- Revenue Next Year
- TCRX $14.01
- NUKK N/A
- P/E Ratio
- TCRX N/A
- NUKK N/A
- Revenue Growth
- TCRX N/A
- NUKK N/A
- 52 Week Low
- TCRX $1.02
- NUKK $1.30
- 52 Week High
- TCRX $9.29
- NUKK $78.32
- Technical
- Relative Strength Index (RSI)
- TCRX 49.42
- NUKK 41.10
- Support Level
- TCRX $1.33
- NUKK $13.05
- Resistance Level
- TCRX $1.49
- NUKK $26.21
- Average True Range (ATR)
- TCRX 0.11
- NUKK 2.40
- MACD
- TCRX 0.02
- NUKK -0.50
- Stochastic Oscillator
- TCRX 69.12
- NUKK 3.88
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
About NUKK Nukkleus Inc.
Nukkleus Inc is a financial technology company that is focused on providing software and technology solutions. The company's operating segment includes General support services and Financial services. General support services include providing software, technology, customer sales and marketing, and risk management technology hardware and software solutions package under a GSA to a related party. Financial services include providing payment services from one fiat currency to another or to digital assets. It generates maximum revenue from the General support services segment. Geographically operates in USA, UK and Malta, with majority of revenue from United Kingdom (UK).